dh@ucsf.edu
(415) 476-9209, 476-4661 (voice)
(415) 731-3612 (fax)

Box 0534, UCSF; San Francisco, CA 94143-0534

Massachusetts Institute of Technology, Cambridge, MA, S.B., 1976, Physics
Harvard University, Cambridge, MA, Ph.D., 1983, Biophysics
Harvard University, 1981-84, Jr. Fellow, Society of Fellows
Professional Experience

(from ~200)

Hanahan, D. 1983. Studies on transformation of E. coli with plasmids. J. Mol. Biol. 166: 557-580.

Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumors in transgenic mice harboring recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122.

Lacey, M., Alpert, S. & Hanahan, D. (1986). The bovine papilloma virus genome elicits skin tumors in transgenic mice. Nature 322, 609-612.

Adams, T., Alpert, S. & Hanahan, D. (1987). Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β-cells. Nature 325, 223-228.

Folkman, J., Watson, K., Ingber, D., & Hanahan, D. l989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.

Bossy-Wetzel, E., Bravo, R., & Hanahan, D. 1992. Transcription factors JunB and c-Jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Gene. Develop., 6:2340-2351.

Jolicoeur, C., Hanahan, D., & Smith, K. 1994. T cell tolerance towards a transgenic β cell antigen and transcription of endogenous pancreatic genes in the thymus. Proc.Nat.Acad.Sci. USA, 91:6707-6711.

Christofori, G., Naik, P., & Hanahan, D. 1994. Insulin-like growth factor II is focally up-regulated and functionally involved as a co-factor in oncogene induced tumorigenesis. Nature, 369:414-418.

Christofori, G., Naik, P., & Hanahan, D. 1995. Deregulation of both imprinted and expressed alleles of the IGF-II gene during β cell tumorigenesis. Nature Genet., 10:196-201.

Parangi, P., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., & Hanahan, D. 1996. Anti-angiogenic therapy of transgenic mice impairs de novo tumor growth. Proc.Nat.Acad.Sci. USA, 93:2002-2007.

Hanahan, D. & Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86:353-364.

Ganss, R., and Hanahan, D. 1998. Tumor microenvironment can restrict the efficacy of activated anti-tumor lymphocytes. Cancer Res., 58:, 4673-4681.

Hanahan, D. 1998. Peripheral antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr. Opin. Immunol. 10: 656-662.

Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on stages of carcinogenesis in mice. Science, 284: 808-812.

Coussens, L., Raymond, W., Bergers, G., Behrendtsen, O., Werb, Z., Caughey, G.H., Hanahan, D. 1999. Inflam-matory mast cells upregulate angiogenesis during squamous epithelial carcinogenesis. Genes Devel 13: 1382-1397.

Hanahan, D. and Weinberg, R. 2000. The hallmarks of cancer. Cell 100: 57-70.

Hanahan, D., Bergers, G. and Bergsland, E. 2000. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105: 1045-1047.

Bergers, G., Brekken, R., McMahon, J., Vu, T., Itoh, T., Tamaki. K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D. 2000. MMP-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol, 2: 737-74

Coussens, L., Tinkle, C., Hanahan, D., & Werb, Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103: 481-490.

Inoue, M., Hager, J., Ferrara, N., Gerber. H.-P., and Hanahan, D. (2001). VEGF-A has a critical, non-redundant role in angiogenic switching and pancreatic β-cell carcinogenesis. Cancer Cell, 1: 193 - 202

Lopez, T., and Hanahan, D. 2002. Elevated levels of Igf-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 1: 339 - 353

Cao, A.Z., Daniel, D., and Hanahan, D. 2002. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11

Bergers,G. and Hanahan, D. 2002 Combining anti-angiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harbor Symposia, 67: 293-300.

Daniel, D., Meyer-Morse, N., Bergsland, E., Dehne, K., Coussens, L.M., & Hanahan, D. (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J.E.M., 197: 1017-1028.

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in tumor vasculature with kinase inhibitors. J.C.I., 111: 1287-95.

Hoffman, J., Giraudo, E., Singh, M., Zhang, L., Inoue, M., Porkka, K., Hanahan, D. and Ruoslahti. E. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 4: 383-91.

Joyce, J., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., Hanahan, D. (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4:393-403.

Joyce, J.A., Baruch, A., Kareem Chehade, K., Nicole Meyer-Morse, N., Fong-Ying Tsai, F.Y., Hager, J., Bogyo, M., & Hanahan, D. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453.

Giraudo, E., Inoue, M., and Hanahan, D. (2004). An amino-bisphosphonate targets MMP9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J.C.I., 114, 623-633.

Argilla, D., Chin, K., Singh, M., Hodgson, G., Bosenberg, M., Ortiz de Solórzano, C., Lockett, S., DePinho, R.A., Gray, J., & Hanahan. D. (2004). Absence of telomerase has minimal effects in mouse models of skin and pancreatic tumorigenesis caused by viral oncogenes: evidence for telomere stabilization in short telomere, telomerase-deficient carcinomas. Cancer Cell, 6, 373-85..

Pietras, K., & Hanahan, D. (2005). A multi-targeted, metronomic-MTD "chemo-switch" regimen is anti-angiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clinical Oncology, 23, 939-52.

Daniel, D, Chiu, C., Giraudo, E., Inoue, M, Mizzen, L., Chu, N.R. & Hanahan, D. (2005). CD4 T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Research, 65, 2018-25..

Joyce, J.A., Freeman, C., Meyer-Morse, N., Parish, C.R., & Hanahan, D. (2005). A functional mimetic implicates heparanase and its target heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene, 24, 4037-5, Apr 4; [Epub ahead of print].

Casanovas, O., Hager, J., Chen, M., & Hanahan, D. (2005). Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene, 24, 6597-604.

Casanovas, O., Hicklin, D., Bergers, G., & Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8, 299-309.

Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T.,Peters, C., Hanahan, D., & Joyce, J.A. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes & Development, 20, 543-546.

Zhang, L., Giraudo, E., Hoffman, J.A., Hanahan D., & Ruoslahti, E. (2006). Lymphatic zip codes in tumors and premalignant lesions. Cancer Research, 66, 5696-706.

Nozawa. H., Chiu, C. & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. PNAS, 103, 12493-98.

1/22/07